All In Biotech

Drug Trial Radar · NCT05065957

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

19

Actual

Start

Mar 29, 2022

Primary completion

Jul 31, 2025

Study completion Jul 31, 2025

Sponsor

Lead sponsor
InnoPharmax Inc.Industry
Sponsor type
Industry
First posted
Oct 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).

Conditions

  • Biliary Tract Cancer

Interventions

  • D07001-softgel capsules + Xeloda (or TS-1)Drug

    D07001-softgel capsules: 3 times per week (on Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of a 21-day cycle, 9 doses per cycle). Xeloda (or TS-1): twice daily for 14 consecutive days followed by 7 days rest (1 treatment cycle)

  • mFOLFOXDrug

    intravenous infusion on Day 1 for 14-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)/ serious adverse event (SAEs)Time frame: From date of informed consent to 30-day follow-up visit for each subject
  2. To assess disease control rate (DCR)Time frame: From date of randomization until the date of first documented progression, date of death from any cause, or date of withdraw the study for each subject, whichever came first, assessed up to 24 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Cancer Center

    Taipei, Taiwan

  • National Taiwan University Hospotal

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.